Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
DURHAM, N.C., March 04, 2016 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company is scheduled to present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 7:30 a.m. Pacific Time.
The link to the live audio webcast and replay of the presentation may be accessed on Heat’s corporate website at http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
